Vaccination immunotherapy - An update

Scandinavian Journal of Surgery

Volumn 93, Issue 2, 2004, Pages 163-169

  Doehn, Christian ^a   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Adjuvant; Dendritic cell; Immunotherapy; Kidney cancer; Metastasis; Progression; Renal cell carcinoma; Survival; Vaccination; Vaccine

Indexed keywords

AUTOLOGOUS RENAL TUMOR CELL VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG MECHANISM; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; NAUSEA; NEPHRECTOMY; PARAMETER; POSTOPERATIVE COMPLICATION; PROGNOSIS; PRURITUS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VACCINATION;

EID: 3142662476     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690409300213     Document Type: Review

References (36)

1. Michael A, Pandha HS: Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncology 2003;4:215-223
2. Gitlitz BJ, Figlin RA: Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003;30:589-600
3. Vieweg J, Dannull J: Tumor vaccines: from gene therapy to dendritic cells - the emerging frontier. Urol Clin North Am 2003;30:633-643
4. Amato RJ: Vaccine therapy for renal cell carcinoma. Rev Urol 2003;5:65-71
5. Tykkä H, Hjelt L, Oravisto KJ, Turunen M, Tallberg T: Disappearence of lung metastases during immunotherapy on five patients suffering from renal carcinoma. Scand J Resp Dis Suppl 1974;89:123-134
6. Tykkä H, Oravisto KJ, Lehtonen T, Sarna S, Tallberg T: Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 1978;4:250-258
7. Tallberg T, Tykkä H, Mahlberg K, Halttunen P, Lehtonen T, Kalima T, Sarna S: Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma patients. A thirteen-year follow-up study. Eur Urol 1985;11:233-243
8. Neidhart JA, Murphy SG, Hennick LA, Wise HA: Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980;46:1128-1134
9. McCune CS, Patterson WB, Henshaw EC: Active specific immunotherapy with tumor cells and Corynebacterium parvum: a phase I study. Cancer 1979;43:1619-1623
10. McCune CS, Schapira DV, Henshaw EC: Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981;47:1984-1987
11. Siemens DR, Ratliff TL: Vaccines in urologic malignancies. Urol Res 2001;29:152-162
12. Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky AI: Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 2003;11:2329-2334
13. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-4566
14. Kjaer M, Frederiksen PL, Engelholm SA: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int J Radiat Oncol Biol Physiol 1987;13:665-672
15. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontanella U, Longo G, Maggioni A: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987;138:1379-1381
16. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Salamini R: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996;77:2560-2566
17. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Permiani G, Marubini E: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425-431
18. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D: Phase III study of Interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2003;21:1214-1222
19. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith, JW, Gordon MS, Margolin KA: Adjuvant high-dose bolus Interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol 2003;21:3133-3140
20. Repmann R, Goldschmidt AJ, Richter A: Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res. 2003;23:969-974
21. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-599
22. Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Wallen EM, Fisher JL, Waugh MG, Truman D, Stempkowski LM, Crosby NA, Heaney JA, Ernstoff MS: Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol 2004;171:1036-1042
23. Pizza G, De Vinci C, Lo Conte G, Mazzuca A, Corrado G, Menniti D, Benati A, Romagnoli P, Fornarola V, Busutti L, Palareti A, Capanna R, Di Maio V, Ratini S, Gulino A, Vacca A, Melchiorri L, Ferrari M, Boriani S, Baricordi RO: Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary report. Folia Biol (Praha) 2003;49:147-159
24. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-2133
25. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003;14:483-494
26. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG: Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003;21:884-890
27. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Milders P, Moldawer N, Tso C-L, Figlin RA: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003;26:412-419
28. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schottker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Ruecker A, Muller S, Sauerbruch T, Schmidt-Wolf IG: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002;51:637-644
29. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002;25:500-508
30. Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA: Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother 2002;25:359-372
31. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369-3376
32. Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W: Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167:1995-2000
33. Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK: Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm 2001;16:47-54
34. Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG: Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 2001;12:267-278
35. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000;46 Suppl:S67-72
36. Schwaab T, Heaney JA, Schned AR, Harris RD, Cole BF, Noelle RJ, Phillips DM, Stempkowski L, Ernstoff MS: A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 2000;163:1322-1327